Business Wire

CA-QUANTA-CLOUD-TECH

29.6.2021 18:02:10 CEST | Business Wire | Press release

Share
QCT, Radisys and Intel Deliver vRAN Solution for 5G

Quanta Cloud Technology (QCT), a global data center solution provider, announced OmniRAN, its virtualized radio access network (vRAN) solution developed with its long-term partners, Intel and Radisys. The solution uses Intel FlexRAN , a cloud-enabled wireless access virtual network functions reference implementation, and Radisys Connect 5G RAN software, a disaggregated RAN architecture for promoting 4G, 5G and IoT to build a cloud-native vRAN based on 3rd Gen Intel Xeon Scalable Processors running on QCT EGX63IS-1U servers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629005459/en/

To deliver low-latency and power-efficient services with the flexibility to increase or decrease capacity based on the volume of real-time traffic demands, Intel’s vRAN dedicated accelerator, ACC100, for forward error correction (FEC) acceleration is also an essential part of the integrated solution. Intel’s 5G optimized network adapter, codenamed Westport Channel, is also implemented for accurate time synchronization without the added complexity or expenses that come with specialty timing hardware. This validated combination on QCT EGX63IS-1U extends distributed unit (DU) capabilities to support multi-cell and multi-RRU 5G scenarios, delivering reliable performance for various network workloads.

As operators are increasingly looking for ways to accelerate their 5G network deployments by leveraging disaggregated and open reference architecture solutions, OpenRAN-based OmniRAN is designed to minimize the challenges of infrastructure deployment and maximize value of ownership. OmniRAN has already been successfully deployed in smart manufacturing use cases such as safety AI for environment control, high-resolution streaming for quality control, AR goggles for maintenance and repair, and autonomous guided vehicles (AGV) for equipment transport. Not only does OmniRAN provide improved performance such as wider coverage and enhanced mobility, but also offer centralized management as well as greater scalability and deployment flexibility while achieving significant cost savings.

“QCT works closely with its partners to ensure that customers can always stay ahead of the game,” said Mike Yang, President of QCT. “Incorporating the newest technologies and features from Intel and Radisys, QCT’s latest vRAN solution improves capital and operational efficiencies by optimizing resource utilization and making software-defined management and orchestration possible.”

“Open 5G networks are the next step for customers across many sectors, and Radisys, along with our partners, is providing open, disaggregated and virtualized RAN solutions to meet varying business demands,” said Munish Chhabra, head of Mobility Software and Services Business, Radisys. “We are excited to power the QCT vRAN solution through our market first Release 16 Radisys 5G software stack. The integrated solution enables mobile operators and enterprises to benefit from reduced costs, improved network efficiencies, and faster time-to-market of new services that open APIs and open architectures provide.”

“This demonstration from Intel, QCT, and Radisys is important for accelerating broader adoption of 5G,” said Cristina Rodriguez, Intel VP and GM of Data Center Group, Wireless Access Network Division. “By defining the FlexRAN reference architecture and collaborating with our Intel Network Builders, Intel is expanding its growing portfolio of technology and ecosystem to ensure interoperability, enhanced performance, and reduced overhead for service providers all over the globe.”

For more information visit https://go.qct.io/telco/ .

About Quanta Cloud Technology (QCT)

Quanta Cloud Technology (QCT) is a global data center solution provider. We combine the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center challenges. QCT serves cloud service providers, telecoms and enterprises running public, hybrid and private clouds.

Intel, the Intel logo and other Intel marks are trademarks of Intel Corporation or its subsidiaries. Other names and brands may be claimed as the property of others.

Link:

ClickThru

Social Media:

https://www.facebook.com/quantacloudtechnology?fref=photo

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye